Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Pennant Group ( (PNTG) ) is now available.
The Pennant Group reported its second quarter 2025 financial results, highlighting a significant increase in revenue and earnings compared to the previous year. Total revenue for the quarter was $219.5 million, marking a 30.1% increase, while net income rose by 24.5% to $7.1 million. The company also provided updated guidance for 2025, anticipating total revenue between $852.8 million and $887.6 million, reflecting strong operational momentum and potential growth opportunities, including a transaction with UnitedHealth Group and Amedisys.
The most recent analyst rating on (PNTG) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Pennant Group stock, see the PNTG Stock Forecast page.
Spark’s Take on PNTG Stock
According to Spark, TipRanks’ AI Analyst, PNTG is a Neutral.
The overall stock score of 64 reflects strong financial performance and positive earnings call highlights, tempered by bearish technical indicators and high valuation metrics. While the company has demonstrated robust growth and profitability, the technical analysis suggests caution due to current market sentiment and trading conditions.
To see Spark’s full report on PNTG stock, click here.
More about Pennant Group
The Pennant Group, Inc. operates as a holding company for independent subsidiaries providing healthcare services through 137 home health and hospice agencies and 61 senior living communities across several states, including Arizona, California, and Texas. Each subsidiary operates independently with its own management and resources.
Average Trading Volume: 253,073
Technical Sentiment Signal: Sell
Current Market Cap: $764.9M
See more insights into PNTG stock on TipRanks’ Stock Analysis page.